Novo Nordisk: Early Payoff From the Oral Wegovy Push
Novo Nordisk's rebound is being driven by strong data and adoption for its oral Wegovy and next-gen obesity candidates. The pullback is over; fundamentals and valuation leave room for a measured long trade. Entry $46.00, stop $42.00, target $56.00 for a mid-term push tied to product uptake and continued data flow.